General
Preferred name
VASOPRESSIN
Synonyms
Argipressin ()
AVP ()
Arg8-vasopressin ()
Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Arg-Gly-NH2(Cys1-Cys6) ()
Argipressin acetate ()
Argipressin acetate (113-79-1(free base)) ()
Argipressin (acetate) ()
Vasostrict ()
Argipressin or lypressin ()
Vasopressin injection ()
Vasopressin component of hbn-1 ()
Leiormone ()
Solute injectable de vasopressine ()
Beta-Hypophamine ()
Inyectable de vasopresina ()
Arginine Vasopressin ()
Vasopressin, unspecified ()
Vasophysin ()
P&D ID
PD014392
CAS
129979-57-3
113-79-1
11000-17-2
83968-48-3
Tags
available
drug
Approved by
FDA
Drug indication
Diabetes insipidus
septic shock
Polyuria
Enuresis
Drug Status
approved
withdrawn
Max Phase
4.0
First approval
2014
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
The approved drug is administered as an injection, as indicated by the INN.
As with all large peptide molecules, there is some ambiguity in representations of the stereochemistry of vasopressin, therefore the chemical structure shown here may differ slightly from that shown on other resouces linked to from the table above. (GtoPdb)
As with all large peptide molecules, there is some ambiguity in representations of the stereochemistry of vasopressin, therefore the chemical structure shown here may differ slightly from that shown on other resouces linked to from the table above. (GtoPdb)
DESCRIPTION
Vasopressin is a cyclic nonapeptide that is synthesized centrally in the hypothalamus. Vasopressin participates in the hypothalamic-pituitary-adrenal axis, and regulates pituitary corticotropin secretion by potentiating the stimulatory effects of corticotropin releasing factor. Vasopressin also can act as a neurotransmitter, exerting its action by binding to specific G protein-coupled receptors[1][2][3].
DESCRIPTION
Argipressin (Arg8-vasopressin) inhibits central corticotropin-releasing hormone. Argipressin acts as a repressor in the regulation of central CRH levels. 5A2-SC8 is an APC-dependent protein.
(TargetMol Bioactive Compound Library)
DESCRIPTION
Vasopressin acetate is a peptide hormone with vasoconstrictive and antidiuretic activities that binds to the vascular arginine vasopressin receptor, V1, with Kd values of 1.31 and 1.44 nM in A7r5 rat aortic smooth muscle cells and neonatal rat cardiomyocytes, respectively
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
18
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
Drug Repurposing Hub
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
Guide to Pharmacology
LSP-MoA library (Laboratory of Systems Pharmacology)
Mcule NIBR MoA Box Subset
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
ReFrame library
Selleckchem Bioactive Compound Library
Withdrawn 2.0
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
44
Molecular Weight
1083.44
Hydrogen Bond Acceptors
16
Hydrogen Bond Donors
15
Rotatable Bonds
19
Ring Count
4
Aromatic Ring Count
2
cLogP
-5.19
TPSA
461.43
Fraction CSP3
0.48
Chiral centers
8.0
Largest ring
20.0
QED
0.03
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
Vasopressin receptor 1
Vasopressin receptor 2
AVPR1A, AVPR1B, AVPR2, OXTR
Endogenous Metabolite
Vasopressin Receptor
5-alpha Reductase
Member status
virtual
MOA
AVPR1A agonist
Vasopressin Receptor agonist
Indication
abdominal distension
ATC
H01BA01
Therapeutic Class
Vasoconstrictor Agents
Pathway
GPCR/G protein
Metabolic Enzyme/Protease
Source data
